Cargando…
Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism
The mechanism of antihypertensive and lipid-lowering drugs on the human organism is still not fully understood. New insights on the drugs’ action can be provided by a metabolomics-driven approach, which offers a detailed view of the physiological state of an organism. Here, we report a metabolome-wi...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4050296/ https://www.ncbi.nlm.nih.gov/pubmed/24816436 http://dx.doi.org/10.1007/s10654-014-9910-7 |
_version_ | 1782319931858092032 |
---|---|
author | Altmaier, Elisabeth Fobo, Gisela Heier, Margit Thorand, Barbara Meisinger, Christine Römisch-Margl, Werner Waldenberger, Melanie Gieger, Christian Illig, Thomas Adamski, Jerzy Suhre, Karsten Kastenmüller, Gabi |
author_facet | Altmaier, Elisabeth Fobo, Gisela Heier, Margit Thorand, Barbara Meisinger, Christine Römisch-Margl, Werner Waldenberger, Melanie Gieger, Christian Illig, Thomas Adamski, Jerzy Suhre, Karsten Kastenmüller, Gabi |
author_sort | Altmaier, Elisabeth |
collection | PubMed |
description | The mechanism of antihypertensive and lipid-lowering drugs on the human organism is still not fully understood. New insights on the drugs’ action can be provided by a metabolomics-driven approach, which offers a detailed view of the physiological state of an organism. Here, we report a metabolome-wide association study with 295 metabolites in human serum from 1,762 participants of the KORA F4 (Cooperative Health Research in the Region of Augsburg) study population. Our intent was to find variations of metabolite concentrations related to the intake of various drug classes and—based on the associations found—to generate new hypotheses about on-target as well as off-target effects of these drugs. In total, we found 41 significant associations for the drug classes investigated: For beta-blockers (11 associations), angiotensin-converting enzyme (ACE) inhibitors (four assoc.), diuretics (seven assoc.), statins (ten assoc.), and fibrates (nine assoc.) the top hits were pyroglutamine, phenylalanylphenylalanine, pseudouridine, 1-arachidonoylglycerophosphocholine, and 2-hydroxyisobutyrate, respectively. For beta-blockers we observed significant associations with metabolite concentrations that are indicative of drug side-effects, such as increased serotonin and decreased free fatty acid levels. Intake of ACE inhibitors and statins associated with metabolites that provide insight into the action of the drug itself on its target, such as an association of ACE inhibitors with des-Arg(9)-bradykinin and aspartylphenylalanine, a substrate and a product of the drug-inhibited ACE. The intake of statins which reduce blood cholesterol levels, resulted in changes in the concentration of metabolites of the biosynthesis as well as of the degradation of cholesterol. Fibrates showed the strongest association with 2-hydroxyisobutyrate which might be a breakdown product of fenofibrate and, thus, a possible marker for the degradation of this drug in the human organism. The analysis of diuretics showed a heterogeneous picture that is difficult to interpret. Taken together, our results provide a basis for a deeper functional understanding of the action and side-effects of antihypertensive and lipid-lowering drugs in the general population. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10654-014-9910-7) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4050296 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-40502962014-06-18 Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism Altmaier, Elisabeth Fobo, Gisela Heier, Margit Thorand, Barbara Meisinger, Christine Römisch-Margl, Werner Waldenberger, Melanie Gieger, Christian Illig, Thomas Adamski, Jerzy Suhre, Karsten Kastenmüller, Gabi Eur J Epidemiol Genetic Epidemiology The mechanism of antihypertensive and lipid-lowering drugs on the human organism is still not fully understood. New insights on the drugs’ action can be provided by a metabolomics-driven approach, which offers a detailed view of the physiological state of an organism. Here, we report a metabolome-wide association study with 295 metabolites in human serum from 1,762 participants of the KORA F4 (Cooperative Health Research in the Region of Augsburg) study population. Our intent was to find variations of metabolite concentrations related to the intake of various drug classes and—based on the associations found—to generate new hypotheses about on-target as well as off-target effects of these drugs. In total, we found 41 significant associations for the drug classes investigated: For beta-blockers (11 associations), angiotensin-converting enzyme (ACE) inhibitors (four assoc.), diuretics (seven assoc.), statins (ten assoc.), and fibrates (nine assoc.) the top hits were pyroglutamine, phenylalanylphenylalanine, pseudouridine, 1-arachidonoylglycerophosphocholine, and 2-hydroxyisobutyrate, respectively. For beta-blockers we observed significant associations with metabolite concentrations that are indicative of drug side-effects, such as increased serotonin and decreased free fatty acid levels. Intake of ACE inhibitors and statins associated with metabolites that provide insight into the action of the drug itself on its target, such as an association of ACE inhibitors with des-Arg(9)-bradykinin and aspartylphenylalanine, a substrate and a product of the drug-inhibited ACE. The intake of statins which reduce blood cholesterol levels, resulted in changes in the concentration of metabolites of the biosynthesis as well as of the degradation of cholesterol. Fibrates showed the strongest association with 2-hydroxyisobutyrate which might be a breakdown product of fenofibrate and, thus, a possible marker for the degradation of this drug in the human organism. The analysis of diuretics showed a heterogeneous picture that is difficult to interpret. Taken together, our results provide a basis for a deeper functional understanding of the action and side-effects of antihypertensive and lipid-lowering drugs in the general population. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10654-014-9910-7) contains supplementary material, which is available to authorized users. Springer Netherlands 2014-05-10 2014 /pmc/articles/PMC4050296/ /pubmed/24816436 http://dx.doi.org/10.1007/s10654-014-9910-7 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Genetic Epidemiology Altmaier, Elisabeth Fobo, Gisela Heier, Margit Thorand, Barbara Meisinger, Christine Römisch-Margl, Werner Waldenberger, Melanie Gieger, Christian Illig, Thomas Adamski, Jerzy Suhre, Karsten Kastenmüller, Gabi Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism |
title | Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism |
title_full | Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism |
title_fullStr | Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism |
title_full_unstemmed | Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism |
title_short | Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism |
title_sort | metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs on the human metabolism |
topic | Genetic Epidemiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4050296/ https://www.ncbi.nlm.nih.gov/pubmed/24816436 http://dx.doi.org/10.1007/s10654-014-9910-7 |
work_keys_str_mv | AT altmaierelisabeth metabolomicsapproachrevealseffectsofantihypertensivesandlipidloweringdrugsonthehumanmetabolism AT fobogisela metabolomicsapproachrevealseffectsofantihypertensivesandlipidloweringdrugsonthehumanmetabolism AT heiermargit metabolomicsapproachrevealseffectsofantihypertensivesandlipidloweringdrugsonthehumanmetabolism AT thorandbarbara metabolomicsapproachrevealseffectsofantihypertensivesandlipidloweringdrugsonthehumanmetabolism AT meisingerchristine metabolomicsapproachrevealseffectsofantihypertensivesandlipidloweringdrugsonthehumanmetabolism AT romischmarglwerner metabolomicsapproachrevealseffectsofantihypertensivesandlipidloweringdrugsonthehumanmetabolism AT waldenbergermelanie metabolomicsapproachrevealseffectsofantihypertensivesandlipidloweringdrugsonthehumanmetabolism AT giegerchristian metabolomicsapproachrevealseffectsofantihypertensivesandlipidloweringdrugsonthehumanmetabolism AT illigthomas metabolomicsapproachrevealseffectsofantihypertensivesandlipidloweringdrugsonthehumanmetabolism AT adamskijerzy metabolomicsapproachrevealseffectsofantihypertensivesandlipidloweringdrugsonthehumanmetabolism AT suhrekarsten metabolomicsapproachrevealseffectsofantihypertensivesandlipidloweringdrugsonthehumanmetabolism AT kastenmullergabi metabolomicsapproachrevealseffectsofantihypertensivesandlipidloweringdrugsonthehumanmetabolism |